πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

2,562 results for β€œCancer” Clear

  1. Endostar

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  2. Ensartinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Entinostat

    KYOWA KIRIN AUSTRALIA PTY LTD

    Advanced or Recurrent Breast Cancer

    phase 2 small molecule completed

    1 trial

  4. Entinostat

    Syndax Pharmaceuticals

    Non Small Cell Lung Cancer

    phase 2 small molecule terminated

    2 trials

  5. Entinostat

    Syndax Pharmaceuticals

    ER+ Breast Cancer

    phase 2 small molecule completed

    1 trial

  6. Entrectinib

    Hoffmann-La Roche

    Breast Cancer

    phase 2 small molecule active

    1 trial

  7. Envafolimab

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  8. Envafolimab

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  9. Enzalutamide

    CORCEPT THERAPEUTICS INC

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  10. Enzalutamide

    BRIGHT MINDS BIOSCIENCES INC.

    Prostate Cancer Metastatic

    phase 2 small molecule completed

    1 trial

  11. Enzalutamide 40mg

    United Therapeutics Europe Ltd

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  12. Erbitux 5 mg/mL solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, Braftovi 75 mg hard capsules

    The George Institute

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  13. Eribulin mesylate

    HALOZYME THERAPEUTICS, INC.

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  14. Erlotinib

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  15. Erlotinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Erlotinib

    United Therapeutics Europe Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  17. Erlotinib

    Hoffmann-La Roche

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  18. Erlotinib

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  19. EstroTep 500 MBq/mL, solution injectable, ELACESTRANT, EXEMESTANE, ELACESTRANT

    Istituto Gentili S.r.l.

    Metastatic hormone receptor-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  20. Etoposide

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule active

    1 trial

  21. Etoposide 20 mg/ml Concentrate for solution for infusion , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Cisplatine Teva 1 mg/ml solution Γ  diluer pour perfusion., ADRIBLASTINE 10 mg, poudre pour solution injectable en flacon, Cyclophosphamide Sandoz, 100 mg/mL, koncentrat do sporzΔ…dzania roztworu do wstrzykiwaΕ„ / do infuzji

    Ningbo Cancer Hospital

    Patients with a confirmed diagnosis of ovarian small cell carcinoma.

    phase 2 small molecule active

    1 trial

  22. Etrumadenant (AB928)

    Arcus Biosciences

    Rectal Cancer

    phase 2 small molecule active

    1 trial

  23. Etrumadenant, Quemliclustat, FLUOROURACIL, BEVACIZUMAB, OXALIPLATIN, CALCIUM FOLINATE, Zimberelimab, Etrumadenant, REGORAFENIB

    Arcus Biosciences

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  24. Evaluation of 64Cu-ATSM PET/CT as a predictor of response to neoadjuvant therapy in locally advanced rectal cancer (TEP-64Cu-ATSM-Rectum)

    CERO THERAPEUTICS HOLDINGS, INC.

    Rectal adenocarcinoma

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources